Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, June 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), GW Pharmaceuticals plc (NASDAQ: GWPH), Endocyte, Inc. (NASDAQ: ECYT) and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3944-100free.
Johnson & Johnson Analyst Notes
On June 17, 2014, Johnson & Johnson announced that the Company will host a conference call on July 15, 2014, at 8:30 a.m. ET, to review its Q2 2014 results. According to the Company, the call will be hosted by Chairman of the Board of Directors and CEO, Alex Gorsky; Vice President, Finance and CFO Dominic Caruso; Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals, Paul Stoffels, M.D.; Worldwide Chairman, Pharmaceuticals Joaquin Duato; and Vice President, Investor Relations Louise Mehrotra. The Company added that the call will be webcast live via its website, where its replay will be available approximately two hours following the conference call. The full analyst notes on Johnson & Johnson are available to download free of charge at:
Merck & Co. Inc. Analyst Notes
On June 9, 2014, Merck & Co. Inc. (Merck), along with Idenix Pharmaceuticals, Inc., announced that they have entered into a definitive agreement. The Company stated that under the agreement, it will acquire Idenix for $24.50 per share in cash in a transaction approved by the Board of Directors of both companies and valued at approximately $3.85 billion. Additionally, the Company stated that Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Idenix Pharmaceuticals, Inc. Commenting on the agreement, Dr. Roger Perlmutter, President, Merck Research Laboratories, stated, "Idenix's investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for millions of patients in need around the world." The transaction is expected to close in Q3 2014. The full analyst notes on Merck are available to download free of charge at:
GW Pharmaceuticals plc Analyst Notes
On June 17, 2014, GW Pharmaceuticals plc (GW) announced that the Company, along with its shareholders, intends to sell 1.7 million American Depositary Shares (ADS) representing ordinary shares of the Company on the NASDAQ Global Market in an underwritten U.S. public offering, subject to market and other conditions. According to the Company, it will grant underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the offering price. Additionally, GW stated that the price for the offering has not been determined yet and there is no assurance whether or when the offering may be completed, or the actual size or terms of the offering. The full analyst notes on GW are available to download free of charge at:
Endocyte, Inc. Analyst Notes
On June 17, 2014, Endocyte, Inc. (Endocyte) announced that the Company has regained worldwide rights to vintafolide in all indications from Merck. According to the Company, Merck, through one of its subsidiaries, has decided not to pursue development of vintafolide, following a comprehensive portfolio assessment. Commenting on the announcement, Endocyte President and CEO, Ron Ellis, said, "We look forward to presenting detailed data from the ongoing Phase 2b TARGET trial at an upcoming scientific conference later this year, which will inform the path forward for vintafolide. We remain confident in our SMDC platform and are in a strong financial position to continue to advance two proprietary SMDCs with the more potent tubulysin warhead. Tubulysin has demonstrated curative activity in preclinical models that were resistant to paclitaxel, cisplatin and vintafolide. These two SMDCs are currently in Phase 1 development: EC1456, targeting the folate receptor, and EC1169, targeting prostate-specific membrane antigen (PSMA)." The full analyst notes on Endocyte are available to download free of charge at:
AVEO Pharmaceuticals, Inc. Analyst Notes
On June 17, 2014, AVEO Pharmaceuticals, Inc.'s (AVEO) stock increased by 11.43%, ending the day at $1.56. Over the past one month trading period, Company stock significantly increased by 38.04% compared to the Nasdaq Composite which went up by 6.03% during the same trading session. The full analyst notes on AVEO are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.